Iatrogenic Diseases: When Healthcare Causes Harm

Iatrogenic diseases represent an important challenge in modern healthcare, arising as unintended consequences of medical interventions intended to benefit patients. With advances in pharmacotherapy, diagnostic procedures, surgical techniques, and healthcare technologies, the scope of potential healthcare-related harm has also expanded. Although adverse drug reactions remain a major component of iatrogenic disease, the concept encompasses a broader range of conditions, including surgical complications, healthcare-associated infections, diagnostic errors, device-related injuries, and system-related failures. This review provides an overview of the evolution and concept of iatrogenesis, its classification, major clinical examples, contributing factors, and approaches for prevention. Particular emphasis is placed on pharmacovigilance, rational use of medicines, and patient-safety practices aimed at reducing preventable harm while improving the quality of healthcare delivery.

In current patient-safety language, iatrogenic disease overlaps

1. World Health Organization. Patient safety [Internet]. Geneva: World Health Organization; 2023 Sep 11 [cited 2026 Jun 23]. Available from: https://www.who.int/news-room/fact-sheets/detail/patient-safety [Google Scholar] [Crossref]

2. World Health Organization. WHO guidelines for safe surgery: safe surgery saves lives [Internet]. Geneva: World Health Organization; 2009 [cited 2026 Jun 23]. Available from: https://www.who.int/publications/i/item/9789241598552 [Google Scholar] [Crossref]

3. World Health Organization. Global patient safety action plan 2021-2030 [Internet]. Geneva: World Health Organization; 2021 [cited 2026 Jun 23]. Available from: https://www.who.int/publications/i/item/9789240032705 [Google Scholar] [Crossref]

4. Peer RF, Shabir N. Iatrogenesis: a review on nature, extent, and distribution of healthcare hazards. J Family Med Prim Care. 2018;7(2):309-314. doi:10.4103/jfmpc.jfmpc_329_17. [Google Scholar] [Crossref]

5. Tripathi KD. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2019. [Google Scholar] [Crossref]

6. Sharma HL, Sharma KK, Joshi HM. Sharma C Sharma's principles of pharmacology. 4th ed. Hyderabad: Paras Medical Publisher; 2023. [Google Scholar] [Crossref]

7. Uppsala Monitoring Centre. WHO Programme for International Drug Monitoring [Internet]. Uppsala: UMC; [cited 2026 Jun 23]. Available from: https://who-umc.org/about-the-who-programme-for-international-drug-monitoring/ [Google Scholar] [Crossref]

8. Central Drugs Standard Control Organization. Pharmacovigilance Programme of India (PvPI) [Internet]. New Delhi: CDSCO, Ministry of Health C Family Welfare, Government of India; [cited 2026 Jun 23]. Available from: https://cdsco.gov.in/opencms/opencms/en/PvPI/ [Google Scholar] [Crossref]

9. Panagioti M, Khan K, Keers RN, Abuzour A, Phipps D, Kontopantelis E, et al. Prevalence, severity, and nature of preventable patient harm across medical care settings: systematic review and meta-analysis. BMJ. 2019;366:l4185. doi:10.1136/bmj.l4185. [Google Scholar] [Crossref]

10. Hodkinson A, Tyler N, Ashcroft DM, Keers RN, Khan K, Phipps D, et al. Preventable medication harm across health care settings: a systematic review and meta-analysis. BMC Med. 2020;18:313. doi:10.1186/s12916-020-01774-9. [Google Scholar] [Crossref]

11. Meara JG, Leather AJM, Hagander L, Alkire BC, Alonso N, Ameh EA, et al. Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development. Lancet. 2015;386(9993):569-624. doi:10.1016/S0140-6736(15)60160-X. [Google Scholar] [Crossref]

12. Kracalik I, Mowla S, Basavaraju SV, Sapiano MRP. Transfusion-related adverse reactions: data from the National Healthcare Safety Network Hemovigilance Module - United States, 2013-2018. Transfusion. 2021;61(5):1424-1434. doi:10.1111/trf.16362. [Google Scholar] [Crossref]

13. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520-1528. doi:10.1056/NEJM200011233432103. [Google Scholar] [Crossref]

14. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102. doi:10.1056/NEJMoa050493. [Google Scholar] [Crossref]

15. Paine MF. Therapeutic disasters that hastened safety testing of new drugs. Clin Pharmacol Ther. 2017;101(4):430-434. doi:10.1002/cpt.632. [Google Scholar] [Crossref]

16. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281(18):1728-1734. doi:10.1001/jama.281.18.1728. [Google Scholar] [Crossref]

17. Srirambabu V. Iatrogenic Diseases: “When Healing Causes Harm” [PowerPoint presentation]. Navi Mumbai: DY Patil School of Medicine; 2026. [Google Scholar] [Crossref]

18. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259. doi:10.1016/S0140-6736(00)02799-9. [Google Scholar] [Crossref]

• Artificial Intelligence in Pharmacology, Drug Safety and Toxicity
• Seroprevalence and Associated Risk Factors of Treponema Pallidum Infection among Pregnant Women Attending Antenatal Clinics in Lokoja, Kogi State
• In Silico Evaluation of Hyptis Verticillata-Derived Phytochemicals Targeting Estrogen Receptor Alpha (Erα) and Progesterone Receptor in Hormone-Dependent Breast Cancer
• A Review Article on AI in Personalized Medicine & Novel Pharamacology
• Leech Therapy (Hirudotherapy): A Comprehensive Systematic Review of Pharmacological Constituents, Mechanisms of Action, Therapeutic Applications, and Safety